search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- corporate advisors
Board of Directors
Steve Harris
Non-Executive Chairman
Mr Harris joined the Board as a
Non-Executive Director in October 2001
and was appointed Non-Executive
Chairman in November 2003. Mr Harris
is currently the Non-Executive Chairman
of Proteome Sciences plc, Cyprotex plc,
and Myotec Therapeutics Limited.
Mr Harris is also a Non-Executive Director
of Advanced Medical Solutions plc and
Phynova plc. Mr Harris has over 40 years'
experience in the pharmaceutical
industry and has held a variety of
positions in both the prescription
and consumer healthcare sectors
with sales, marketing and general
management experience with
Merck Sharp and Dohme, Eli Lilly,
Boots and Reckitt and Colman (now
Reckitt Benckiser). Before setting up
his own consultancy practice in 1995
to work as a Non-Executive Director
in the life-science industry, Mr Harris
was Development and Licensing
Director for Medeva plc.
Jerry Randall
Chief Financial Officer
Mr Randall became Chief Financial
Officer in August 2000 when he
completed the management
buy-in with Dr Flynn. Before joining
Sinclair Pharma, Mr Randall worked
in corporate finance, setting up
and running the Bristol office of
Gambit Corporate Finance. Prior to
that, Mr Randall had been involved in
two other buy-ins and acted as advisor
to both private and quoted companies
between 1993 and 2000, in both the
capacity as nominated advisor and in
practice with KPMG. During this period,
Mr Randall was involved in a number
of flotations and transactions on the
Official List, Unlisted Securities
Market and AIM, as well as raising
private equity. Mr Randall qualified as
a chartered accountant with KPMG
in 1990.
Jean-Charles Tschudin
Non-Executive Director
Mr Tschudin joined the Board in
November 2007. He has extensive
experience in the pharmaceutical
industry at a senior executive level
on three continents and was recently
President and Chief Operating Officer
of Yamanouchi Europe, the largest
Japanese company in Europe (now
Astellas). He has also held senior
positions at Johnson & Johnson,
Schering-Plough, Syntex and
Cardinal Health. Mr Tschudin is
currently Non-Executive Director of
SkyePharma plc and he also consults
for the pharma industry.
Michael Flynn
Chief Executive Officer
Dr Flynn became Chief Executive Officer
in August 2000 following a management
buy-in of Sinclair Pharmaceuticals Limited,
which he led. Between 1998 and 2000,
Dr Flynn privately acquired the rights
to a portfolio of products, which he
brought to the Group. From June to
November 1998, Dr Flynn was acting
Chief Executive Officer of Cortecs
Group plc where he held the position
of President between 1992 and
June 1998 and of Director between
1986 and 1992. Between 1976 and
1986, he was Medical Director and
President of Technology International
Limited, a contract research organisation
that Dr Flynn co-founded. Prior to
1976, Dr Flynn had worked as
Senior Medical Advisor to Crookes
Laboratories Limited, established
Duphar Limited in the UK and spent
approximately five years in the Clinical
Research Department of Philips Duphar
in Holland. Dr Flynn has spent over
30 years in the pharmaceutical industry
and has served on the Board of Directors
of approximately 30 private companies
involved in the healthcare sector. Dr Flynn
was elected a Fellow by Distinction of
the Faculty of Pharmaceutical Medicine
of the Royal College of Physicians in
2001 and qualified as a physician from
Kings College Hospital, London.
Grahame Cook
Senior Independent Director
Mr Cook joined the Board in July 2004.
He has over 18 years' experience in
investment banking, advising on a
wide number of mergers and
acquisitions and capital market
transactions in the US and Europe.
He was Global CEO of West LB Panmure,
Managing Director of Capital Markets
and on the Global Investment Banking
Committee at UBS. He has advised
on a number of transactions in the
pharmaceuticals and biotechnology
sectors across Europe and the US,
including private equity investments,
IPOs and secondary offerings. Mr Cook
was a founder member of the LSE's
TechMARK Advisory Committee,
and holds an MA, double first, from
Oxford University. He is currently a
Non-Executive Director of Antisonna plc.
Penny Freer
Non-Executive Director
Ms Freer has been involved in investment banking for 20 years. She co-founded The Capital Markets Group and until 2004 was Head of Equities for Robert W. Baird in London. She is a Non-Executive Director of Empresaria Group plc.